Search

Culmen International LLC in Silver Springs, MD, is seeking a Junior Scientist II – Phage Molecular Biologist and a Junior Scientist I – Phage Immunologist to work on phage-based therapies targeting pathogens relevant to military health, dev

Cytophage partnered with Dr. Marisa Azad at The Ottawa Hospital to deliver the first phage therapy in Canada for a patient with a severe hardware-associated joint infection. The phage treatment was produced by Cytophage, targeted Staphyloco

University of Leicester, UK is hiring a Research Technician to optimize phage production processes, focusing on scaling up phage amplification and purification to meet therapeutic demands within the Centre for Phage Research.

Wondering how phage therapy startups raise money? PhageLab recently raised $11M, and this ‘pitch deck teardown’ blog post goes through the pitch deck they used to convince investors, which slides pack the most punch, and other tips.

FDA (Silver Spring, Maryland) is offering a postbac fellowship to develop and characterize phage therapy for decolonizing Vancomycin-resistant Enterococci, focusing on overcoming bacterial resistance.

BiomX and Adaptive Phage Therapeutics have announced they will merge! They concurrently announce new financing of $50 million, which will help advance the combined company’s two Phase 2 assets: one for CF and one for diabetic foot ulcers.

Armata Pharmaceuticals has announced a $35 million credit agreement with its largest shareholder, Innoviva.

We are urgently seeking Achromobacter phages for a patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving the patient's strain and testing your phages - By helping spre

We are urgently seeking Achromobacter phages for a patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving the patient's strain and testing your phages - By helping spre

We are urgently seeking Achromobacter phages for a patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving the patient's strain and testing your phages - By helping spre

University of Nottingham, UK, is offering a PhD Studentship to develop phage therapy strategies against C. difficile, involving synthetic biology, CRISPR/Cas genome editing, and microbiology.

FDA (Silver Spring, Maryland) is offering a postbac fellowship to develop and characterize phage therapy for decolonizing Vancomycin-resistant Enterococci, focusing on overcoming bacterial resistance.

This week on PhageCast, the team talked to Paul Turner about how his lab is predicting the trade-offs of bacterial resistance to phage, to achieve killing by reversing the antibiotic resistance. They also covered how these findings are tran

Pherecydes has a new phage therapy patent. It covers new S. aureus phages and their manufacture and combination for use in phage therapy and as a companion diagnostic.

PhageCast recently interviewed Lorenzo Corsini about why Staph phages don’t work well in plasma or synovial fluid, and talked to Jean-Paul Pirnay (2-part series) about the Queen Astrid Military Hospital’s first 100 documented cases of phage

Madison Stellfox and colleagues at the University of Pittsburgh published a new paper on phage-antibiotic combination therapy for recurrent E. faecium. Phages were administered to a patient with increasingly severe E. faecium bloodstream in

Silvia Würstle and colleagues at the Center for Phage Biology & Therapy at Yale University published a paper on their optimized pipeline for emergency phage therapy against P. aeruginosa. Their pipeline includes evaluation of useful evolved

Julie Fletcher and colleagues at the University of Exeter published a paper showcasing their Citizen Phage Library's end-to-end approach for rapidly isolating phages and purifying them for patient use. They’ve responded to four Phage Direct

The Alfred and Monash University collaboration had explored phage therapy for four patients by February 2024, with patients considered eligible only on compassionate grounds in Australia. The team described the approach as experimental. Alf

In this preprint, intravenously administered antipseudomonal phage LPS-5 had blood half-lives of 3.45 and 3.66 hours in wild-type and neutropenic mice, suggesting neutrophil phagocytosis is not a major driver of phage clearance. A gap betwe